Physician profile
Robert T Lin
NPI 1265579924
$13,616.08
in general payments reported to CMS, 2019-2025
56 companies · $2,185 in 2025
The $2,185 reported for 2025 was more than what 94% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,829 · 2020: $1,862 · 2021: $2,218 · 2022: $1,801 · 2023: $1,903 · 2024: $1,818 · 2025: $2,185.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,878 · Education: $27.78.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,878.32 |
| Education | $27.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,751.10 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Pfizer INC. | $1,272.22 | 2019-2025 | |
| Novo Nordisk INC | $1,252.99 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $1,240.81 | 2019-2025 | |
| Amgen INC. | $1,086.72 | 2019-2025 | Repatha, Otezla, Repatha |
| Lilly USA, LLC | $996.08 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbott Laboratories | $468.77 | 2021-2025 | Freestyle Libre 3, Freestyle Libre 2 |
| Glaxosmithkline, LLC. | $328.22 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Merck Sharp & Dohme LLC | $310.31 | 2019-2025 | Verquvo, Capvaxive, Gardasil 9 |
| Janssen Pharmaceuticals, INC | $285.25 | 2019-2021 | |
| Mylan Specialty L.P. | $278.82 | 2019-2024 | Yupelri |
| Biohaven Pharmaceuticals, INC. | $260.31 | 2021 | |
| Alkermes, INC. | $255.74 | 2022-2024 | Aristada, Lybalvi |
| Allergan, INC. | $220.06 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $217.99 | 2019-2023 |
Show all 56 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Lin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.